Search
Phosphoric acid
go.drugbank.com/drugs/DB09394ApprovedInvestigationalPhosphoric acid is a sequestering agent which binds many divalent cations, including Fe++, Cu++, Ca++, and Mg++.
Atosiban
go.drugbank.com/drugs/DB09059ApprovedInvestigationalAtosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor.
Rabies virus inactivated antigen, A
go.drugbank.com/drugs/DB10283ApprovedInvestigationalIt is an active immunization against rabies that can be administered pre- or post-exposure to the rabies virus. … Rabies virus inactivated antigen, A is an inactivated virus vacine for the intramuscular injection.
Products: ABHAYRAB 2.5 IU/0.5 ML IM/ID ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN LİYOFİLİZE TOZ VE ÇÖZÜCÜ, 1 ADETProthrombin
go.drugbank.com/drugs/DB11311ApprovedInvestigationalProthrombin Complex Concentrate (Human), is indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.
Mixtures: Beriplex P/n 500, Beriplex P/n 1000Eprosartan
go.drugbank.com/drugs/DB00876ApprovedInvestigationalEprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system.
Synonyms: (E)-2-butyl-1-(p-carboxybenzyl)-α-2-thenylimidazole-5-acrylic acidFosfomycin
go.drugbank.com/drugs/DB00828ApprovedInvestigational[A230348] In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring. … [A230348] Due to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated
Products: FOSFOCIL GUDibotermin alfa
go.drugbank.com/drugs/DB11639ApprovedInvestigationalIn a prospective clinical study of patients with an open tibial fracture, administration of dibotermin alfa resulted in faster fracture- or wound-healing, significantly fewer secondary invasive interventions
PF-04620110
go.drugbank.com/drugs/DB14887InvestigationalPF-04620110 is under investigation in clinical trial NCT01146327 (A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects).
PF-04634817
go.drugbank.com/drugs/DB14955InvestigationalPF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects).
PF-07038124
go.drugbank.com/drugs/DB19143InvestigationalPF-07038124 is under investigation in clinical trial NCT05298033 (Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo).